About
Mapp Biopharmaceutical was created to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company has been developing an Ebola therapy for more than a decade and has been working with the United States and Canadian governments to develop this therapy. Mapp Biopharmaceutical was founded in 2003 by Kevin Whaley and Larry Zeitlin. It is headquartered in San Diego, C.A.
Position in the VCSift Database
- • 4,609 investors in VCSift focus on the biotech sector.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- biotech
- Location
- San Diego, US
Contact Information
linkedin.com/in/••••••••
Find more investors like Mapp
Search Investors